Newzen-138

Newzen-138 is an investigational **small molecule** being developed by **NewzenPharma** for **castrate-resistant prostate cancer**. Based on the company pipeline description, the program is intended to target **base excision repair** and broader **DNA repair** biology in tumor cells, with the goal of reducing BER capacity and impairing cancer-cell DNA damage repair while sparing normal cell growth. The proposed therapeutic rationale is to exploit DNA repair vulnerabilities in advanced prostate cancer and potentially slow tumor progression, metastasis, and treatment resistance. Publicly provided information appears limited to company pipeline-level disclosures, and no specific molecular target, formulation, route, or clinical phase has been clearly disclosed in the provided materials.